Your browser doesn't support javascript.
loading
Improving adenoviral vectors and strategies for prostate cancer gene therapy
Tamura, Rodrigo Esaki; de Luna, Igor Vieira; Lana, Marlous Gomes; Strauss, Bryan E.
  • Tamura, Rodrigo Esaki; Universidade de Sao Paulo. Instituto do Cancer do Estado de Sao Paulo (ICESP). Laboratório de Vetores Virais, Centro de Investigação Translacional em Oncologia. Sao Paulo. BR
  • de Luna, Igor Vieira; Universidade de Sao Paulo. Instituto do Cancer do Estado de Sao Paulo (ICESP). Laboratório de Vetores Virais, Centro de Investigação Translacional em Oncologia. Sao Paulo. BR
  • Lana, Marlous Gomes; Universidade de Sao Paulo. Instituto do Cancer do Estado de Sao Paulo (ICESP). Laboratório de Vetores Virais, Centro de Investigação Translacional em Oncologia. Sao Paulo. BR
  • Strauss, Bryan E; Universidade de Sao Paulo. Instituto do Cancer do Estado de Sao Paulo (ICESP). Laboratório de Vetores Virais, Centro de Investigação Translacional em Oncologia. Sao Paulo. BR
Clinics ; 73(supl.1): e476s, 2018. graf
Article in English | LILACS | ID: biblio-952839
ABSTRACT
Gene therapy has been evaluated for the treatment of prostate cancer and includes the application of adenoviral vectors encoding a suicide gene or oncolytic adenoviruses that may be armed with a functional transgene. In parallel, versions of adenoviral vector expressing the p53 gene (Ad-p53) have been tested as treatments for head and neck squamous cell carcinoma and non-small cell lung cancer. Although Ad-p53 gene therapy has yielded some interesting results when applied to prostate cancer, it has not been widely explored, perhaps due to current limitations of the approach. To achieve better functionality, improvements in the gene transfer system and the therapeutic regimen may be required. We have developed adenoviral vectors whose transgene expression is controlled by a p53-responsive promoter, which creates a positive feedback mechanism when used to drive the expression of p53. Together with improvements that permit efficient transduction, this new approach was more effective than the use of traditional versions of Ad-p53 in killing prostate cancer cell lines and inhibiting tumor progression. Even so, gene therapy is not expected to replace traditional chemotherapy but should complement the standard of care. In fact, chemotherapy has been shown to assist in viral transduction and transgene expression. The cooperation between gene therapy and chemotherapy is expected to effectively kill tumor cells while permitting the use of reduced chemotherapy drug concentrations and, thus, lowering side effects. Therefore, the combination of gene therapy and chemotherapy may prove essential for the success of both approaches.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Prostatic Neoplasms / Genetic Therapy / Adenoviridae / Carcinoma, Non-Small-Cell Lung / Genetic Vectors / Lung Neoplasms Limits: Humans / Male Language: English Journal: Clinics Journal subject: Medicine Year: 2018 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade de Sao Paulo/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Prostatic Neoplasms / Genetic Therapy / Adenoviridae / Carcinoma, Non-Small-Cell Lung / Genetic Vectors / Lung Neoplasms Limits: Humans / Male Language: English Journal: Clinics Journal subject: Medicine Year: 2018 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade de Sao Paulo/BR